2024
Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
Delgado-Coka L, Roa-Peña L, Babu S, Horowitz M, Petricoin E, Matrisian L, Blais E, Marchenko N, Allard F, Akalin A, Jiang W, Larson B, Hendifar A, Picozzi V, Choi M, Shroyer K, Escobar-Hoyos L. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. American Journal Of Clinical Pathology 2024, 162: 314-326. PMID: 38642081, PMCID: PMC11369068, DOI: 10.1093/ajcp/aqae038.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaPredictive biomarkersDuctal adenocarcinomaK17 expressionKeratin 17Gemcitabine-based therapyGemcitabine-based chemotherapyBasal molecular subtypeTumor mutation statusResponse to chemotherapyPancreatic ductal adenocarcinoma cellsThreshold of expressionChemotherapeutic regimensAdvanced-stageClinicopathological variablesMutation statusPrognostic stratificationMolecular subtypesShorter survivalLonger survivalFormalin-FixedImmunohistochemical testsPredictive valuePatientsTherapeutic interventions
2023
Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer Committee
Talbot L, Lautz T, Aldrink J, Ehrlich P, Dasgupta R, Mattei P, Tracy E, Glick R, Grant C, Brown E, Christison-Lagay E, Rodeberg D. Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer Committee. Journal Of Pediatric Surgery 2023, 58: 2119-2127. PMID: 37550134, DOI: 10.1016/j.jpedsurg.2023.07.001.Peer-Reviewed Original ResearchAPSA Cancer CommitteeClass of immunotherapyT-cell therapyCancer CommitteePediatric malignanciesChimeric antigen receptor T-cell therapyMonoclonal antibody checkpoint inhibitorsTransgenic T cell receptorBispecific T-cell engagersCell therapyEarly phase clinical trialsYoung adultsConventional chemotherapeutic regimensDisease-related deathT-cell engagersClass of therapyT cell receptorCare of childrenCheckpoint inhibitorsAdverse eventsMetastatic diseaseSystemic treatmentChemotherapeutic regimensSurgical interventionClinical trials
2019
Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young women
Buza N, Baine I, Hui P. Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young women. Modern Pathology 2019, 32: 1271-1280. PMID: 31028360, DOI: 10.1038/s41379-019-0275-z.Peer-Reviewed Original ResearchConceptsGestational choriocarcinomaLung carcinomaLung massClinical historyLung tumorsGestational originSerum beta-hCG levelsYoung womenTrophoblastic differentiationMetastatic gestational choriocarcinomaSerum beta-hCGBeta-hCG levelsEvidence of diseaseUnique diagnostic challengePrimary lung carcinomaGestational trophoblastic neoplasiaDifferent chemotherapeutic regimensDifferent primary sitesWedge resectionBeta-hCGFemale patientsMetastatic choriocarcinomaThird patientChemotherapeutic regimensImmunophenotypical features
2018
Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma
De Carvalho Fischer C, Hu Y, Morreale M, Lin WY, Wali A, Thakar M, Karunasena E, Sen R, Cai Y, Murphy L, Zahnow CA, Keer H, Thakar M, Ahuja N. Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma. Oncotarget 2018, 9: 19379-19395. PMID: 29721210, PMCID: PMC5922404, DOI: 10.18632/oncotarget.25056.Peer-Reviewed Original ResearchDNA methyltransferase inhibitorEpigenetic modulatorsLMS cell linesCell linesMES-SAApoptotic pathwayCell cycleMethyltransferase inhibitorCell survivalDifferentiation patternsEpigenetic agentsNovel chemotherapeutic regimensPotential therapeutic applicationsLeiomyosarcoma cell lineRare mesenchymal neoplasmSpectrum of sensitivityChemotherapeutic regimensPoor prognosisMesenchymal neoplasmsSensitive linesTumor growthGuadecitabineTherapeutic applicationsAdditional studiesModulator
2016
Cost Differential of Chemotherapy for Solid Tumors.
Nadeem H, Jayakrishnan T, Rajeev R, Johnston F, Gamblin T, Turaga K, Nadeem H, Jayakrishnan T, Rajeev R, Johnston F, Gamblin T, Turaga K. Cost Differential of Chemotherapy for Solid Tumors. JCO Oncology Practice 2016, 12: e299-307, 251. PMID: 26860586, DOI: 10.1200/jop.2015.006700.Peer-Reviewed Original ResearchConceptsSolid tumorsCurative therapyNational Comprehensive Cancer Network guidelinesNational Comprehensive Cancer NetworkBreast cancer regimensCancer therapy regimensComprehensive Cancer NetworkCost of chemotherapyUS adult malesMetastatic cancer therapyCancer regimensChemotherapy regimensChemotherapeutic regimensTherapy regimensNetwork guidelinesBaseline drugRegimensChemotherapyTreatment periodCancer therapyCancer NetworkMedian costPractice patternsTumorTherapy
2015
Classic reaction kinetics can explain complex patterns of antibiotic action
Abel Zur Wiesch P, Abel S, Gkotzis S, Ocampo P, Engelstädter J, Hinkley T, Magnus C, Waldor MK, Udekwu K, Cohen T. Classic reaction kinetics can explain complex patterns of antibiotic action. Science Translational Medicine 2015, 7: 287ra73. PMID: 25972005, PMCID: PMC4554720, DOI: 10.1126/scitranslmed.aaa8760.Peer-Reviewed Original ResearchConceptsOptimal dosing strategiesAntibiotic treatment strategiesTime-kill curvesAntibiotic effectGrowth suppressionCell formationChemotherapeutic regimensClinical trialsDosing strategiesTreatment strategiesTuberculosis therapyPersister cell formationDrug effectsBacterial infectionsVariety of antibioticsGhrelin Partially Protects Against Cisplatin-Induced Male Murine Gonadal Toxicity in a GHSR-1a-Dependent Manner1
Whirledge SD, Garcia JM, Smith RG, Lamb DJ. Ghrelin Partially Protects Against Cisplatin-Induced Male Murine Gonadal Toxicity in a GHSR-1a-Dependent Manner1. Biology Of Reproduction 2015, 92: 76, 1-11. PMID: 25631345, PMCID: PMC4367966, DOI: 10.1095/biolreprod.114.123570.Peer-Reviewed Original ResearchConceptsTesticular cell deathTesticular damageGonadal toxicityEpididymal weightGrowth hormone secretagogue receptorDose-dependent side effectsCisplatin-induced cachexiaTime of euthanizationHigh cumulative doseBody weight homeostasisCell deathCisplatin-induced testicular damageNovel therapeutic approachesGonadotoxin exposurePermanent azoospermiaGhrelin administrationSubsequent infertilityChemotherapeutic drug cisplatinChemotherapeutic regimensCisplatin administrationGhrelin actionWeight homeostasisCumulative doseIntraperitoneal administrationSecretagogue receptor
2014
Cost differential among systemic therapies for colon cancer.
Nadeem H, Jayakrishnan T, Gamblin T, Turaga K. Cost differential among systemic therapies for colon cancer. Journal Of Clinical Oncology 2014, 32: 583-583. DOI: 10.1200/jco.2014.32.3_suppl.583.Peer-Reviewed Original ResearchNational Comprehensive Cancer NetworkMetastatic colon cancerColon cancerTreatment of metastatic colon cancerNational Comprehensive Cancer Network guidelinesMedian costSystemic therapy regimensComprehensive Cancer NetworkChemotherapy regimensChemotherapeutic regimensSystemic therapyAdjuvant treatmentSystemic treatmentTherapy regimensAlternative chemotherapeutic strategiesToxicity profileChemotherapeutic strategiesRegimensAmerican patientsCancer NetworkTherapeutic benefitCancerHealth care costsReduce health care costsChemotherapy
2012
Management of Pancreatoblastoma in Children and Young Adults
Glick RD, Pashankar FD, Pappo A, LaQuaglia MP. Management of Pancreatoblastoma in Children and Young Adults. Journal Of Pediatric Hematology/Oncology 2012, 34: s47-s50. PMID: 22525406, DOI: 10.1097/mph.0b013e31824e3839.Peer-Reviewed Original ResearchConceptsAppropriate cross-sectional imagingComplete surgical resectionLarge retroperitoneal massMalignant pancreatic tumorsGoal of therapyHigh recurrence rateRare childhood tumorCross-sectional imagingYoung childrenAdjuvant chemotherapyCurative resectionNeoadjuvant chemotherapyMetastatic diseaseSurgical resectionInitial diagnosisRetroperitoneal massChemotherapeutic regimensRecurrence rateMean ageRare tumorPancreatic tumorsTissue diagnosisChildhood tumorsSectional imagingTumors
2011
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
Galsky M, Hahn N, Rosenberg J, Sonpavde G, Hutson T, Oh W, Dreicer R, Vogelzang N, Sternberg C, Bajorin D, Bellmunt J. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy. Journal Of Clinical Oncology 2011, 29: 2432-2438. PMID: 21555688, DOI: 10.1200/jco.2011.34.8433.Peer-Reviewed Original ResearchConceptsMetastatic urothelial carcinomaUrothelial carcinomaChemotherapeutic regimensNew York Heart Association class III heart failureResults of prospective clinical trialsEastern Cooperative Oncology Group performance statusClinical trialsCisplatin-based combination chemotherapyClass III heart failureMetastatic urothelial cancerCisplatin-based chemotherapyIII heart failurePhase II trialPhase III trialsFirst-line treatmentProspective clinical trialSubgroup of patientsProportion of patientsTreatment of patientsCombination chemotherapyUniform definitionII trialIII trialsHearing lossUrothelial cancerPeripheral T-cell lymphoma
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011, 117: 6756-6767. PMID: 21493798, DOI: 10.1182/blood-2010-05-231548.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaStandard chemotherapeutic regimensBest treatment strategyMore effective therapiesHistone deacetylase inhibitorsWorld Health OrganizationAbundance of drugsAggressive diseaseChemotherapeutic regimensPoor outcomeTreatment optionsClinical trialsEffective therapyTreatment strategiesTherapeutic approachesPrognostic issuesDeacetylase inhibitorsLymphoma classificationMonoclonal antibodiesGene expression profilingHeterogeneous groupHealth OrganizationProteasome inhibitorsDisease biology
2009
Beyond Doublet Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Combination of Targeted Agents with First-Line Chemotherapy
Herbst RS, Lynch TJ, Sandler AB. Beyond Doublet Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Combination of Targeted Agents with First-Line Chemotherapy. Clinical Lung Cancer 2009, 10: 20-27. PMID: 19289368, DOI: 10.3816/clc.2009.n.003.Peer-Reviewed Original ResearchConceptsBest supportive careOverall survivalMetastatic NSCLCLung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerPhase III clinical trialsPlatinum-based doubletsAddition of bevacizumabFirst-line chemotherapyPlatinum-based regimensProgression-free survivalFirst-line treatmentCell lung cancerOverall patient survivalTyrosine kinase inhibitorsInhibition of componentsMatrix metalloproteinase inhibitorsDoublet chemotherapySystemic chemotherapyMedian survivalSupportive careMost patientsTargeted agentsChemotherapeutic regimens
2008
Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents
Lilenbaum R, Herbst R. Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. Clinical Pulmonary Medicine 2008, 15: 352-358. DOI: 10.1097/cpm.0b013e31818cd61f.Peer-Reviewed Original ResearchCell lung cancerMetastatic NSCLCOverall survivalLung cancerPatient outcomesAdvanced metastatic NSCLCThird-line settingBest supportive careProgression-free survivalAntiangiogenic agent bevacizumabOverall patient survivalPatient selection criteriaOngoing clinical trialsEpidermal growth factor receptorGrowth factor receptorRefractory settingAgent bevacizumabSupportive careTargeted agentsOptimal therapyChemotherapeutic regimensPatient survivalClinical trialsResponse rateMaximal benefit
2000
In vitro collection and posttransfusion engraftment characteristics of MNCs obtained by using a new separator for autologous PBPC transplantation
Snyder EL, Baril L, Cooper DL, Min K, Mechanic S, Stoddart L, Burtness B, Seagraves P, Debelak J, Gudino M, McCullough J. In vitro collection and posttransfusion engraftment characteristics of MNCs obtained by using a new separator for autologous PBPC transplantation. Transfusion 2000, 40: 961-967. PMID: 10960524, DOI: 10.1046/j.1537-2995.2000.40080961.x.Peer-Reviewed Original ResearchConceptsEngraftment characteristicsPBPC collectionHigh-dose myeloablative chemotherapyPeripheral blood progenitor cell collectionAutologous PBPC transplantAutologous PBPC transplantationSerious adverse eventsAutologous transplant patientsNumber of CD34Cell separatorProgenitor cell collectionShort-term engraftmentAmicus deviceBlood cell separatorAmicus SeparatorPBPC rescuePBPC transplantPBPC transplantationTransplant patientsAdverse eventsMyeloablative chemotherapyMyeloablative therapyOncology patientsChemotherapeutic regimensPlatelet count
1990
Unilateral Cutaneous Emboli of Aspergillus
Watsky K, Eisen R, Bolognia J. Unilateral Cutaneous Emboli of Aspergillus. JAMA Dermatology 1990, 126: 1214-1217. PMID: 2396839, DOI: 10.1001/archderm.1990.01670330094015.Peer-Reviewed Case Reports and Technical NotesConceptsLeft upper extremityLeft subclavian arteryBone marrow transplantationAcute nonlymphocytic leukemiaSkin biopsy specimenBroad-spectrum antibioticsCutaneous emboliHyphae consistentPulmonary aspergillomaSubclavian arteryMarrow transplantationPurpuric maculesLesional skinChemotherapeutic regimensNonlymphocytic leukemiaBiopsy specimenUpper extremityFrozen sectionsDay 53White womenLeft handNecrotic centerEmboliFeverMagnetic resonance
1981
High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.
Jones R, Collins J, Myers C, Brooks A, Hubbard S, Balow J, Brennan M, Dedrick R, DeVita V. High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Research 1981, 41: 55-9. PMID: 7448776.Peer-Reviewed Original ResearchConceptsEpisodes of bacterial peritonitisNovel treatment modalitiesTotal body clearanceIntraperitoneal chemotherapyPeritoneal irritationChemotherapeutic regimensMethotrexate clearanceBacterial peritonitisOvarian cancerMalignant melanomaTreatment modalitiesLocal toxicitySystemic toxicityPlasma levelsPeritoneal cavitySystemic circulationTreatment cyclesPlasma concentrationsMethotrexate concentrationsTherapeutic benefitBody clearancePatientsMethotrexateChemotherapyPeritonitis
1978
Diffuse histiocytic lymphoma involving the gastrointestinal tract
Hande K, Fisher R, Devita V, Chabner B, Young R. Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer 1978, 41: 1984-1989. PMID: 348299, DOI: 10.1002/1097-0142(197805)41:5<1984::aid-cncr2820410544>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsDiffuse histiocytic lymphomaBowel perforationComplete remissionSurgical resectionHistiocytic lymphomaGastrointestinal tractActive chemotherapeutic regimensMassive intestinal hemorrhageMajority of patientsResults of stagingRigorous stagingGastrointestinal lymphomaSystemic chemotherapySystemic therapyBowel lesionsChemotherapeutic regimensIntestinal hemorrhageDrug therapyRadiation therapyPatientsTumor resistanceLymphomaTherapyRelative rarityWidespread disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply